Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction

4 Jul 2024

Abstract excerpt

Sickle cell disease (SCD) is a prevalent, life-threatening condition attributable to a heritable mutation in β-hemoglobin. Therapeutic induction of fetal hemoglobin (HbF) can ameliorate disease complications and has been intently pursued. However, safe and effective small-molecule inducers of HbF remain elusive. We report the discovery of dWIZ-1 and dWIZ-2, molecular glue degraders of the WIZ transcription factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38963839
DOI: 10.1126/science.adk6129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin inductionPMID 38963839Read ↗

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell DiseaseSemantic proximity Read ↗

DCN1 inhibitor induces fetal hemoglobin through self-limited regulation of CUL3 neddylationSemantic proximity Read ↗

Targeted Therapeutic Strategies for Fetal Hemoglobin InductionSemantic proximity Read ↗

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Semantic proximity Read ↗

Regulation of the fetal hemoglobin silencing factor BCL11ASemantic proximity Read ↗

A Cell-Based High-Throughput Screen for Novel Chemical Inducers of Fetal Hemoglobin for Treatment of HemoglobinopathiesSemantic proximity Read ↗

Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell diseaseSemantic proximity Read ↗

Elevating fetal hemoglobin: recently discovered regulators and mechanismsSemantic proximity Read ↗

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseSemantic proximity Read ↗

Dissecting the epigenetic regulation of the fetal hemoglobin genes to unravel a novel therapeutic approach for β-hemoglobinopathiesSemantic proximity Read ↗

Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse modelSemantic proximity Read ↗

Structural basis for human ZBTB7A action at the fetal globin promoterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.